AIR FORCE HEALTH STUDY

An Epidemiologic Investigation of
Health Effects in Air Force Personnel
Following Exposure to Herbicides

SAIC Team
William D. Grubbs, Ph.D.
Michael B. Lustik, M.S.
Amy S. Brockman, M.S.
Scott C. Henderson, M.S.
Frank R. Burnett, M.S.
Rebecca G. Land, M.S.
Dawn J. Osborne, M.S.
Vanessa K. Rocconi, B.S.
Margaret E. Schrieber, B.A.
David E. Williams, M.D., SCRF

Air Force Team
Col William H. Wolfe, M.D., M.P.H.
Joel E. Michalek, Ph.D.
Col Judson C. Miner, D.V.M., M.P.H.
Col Gary L. Henriksen, M.D., M.P.H.
Lt Col James A. Swaby, Ph.D., B.C.E.

Project Manager: Manager E.B. Owens, Ph.D.
Statistical Task Manager: W.D. Grubbs
SAIC Editor: Jean M. Ault, B.A.

Program Manager: R.W. Ogershok

SCIENCE APPLICATIONS INTERNATIONAL
1710 Goodridge Drive
McLean, Virginia 22102

in conjunction with:

SCRIPPS CLINIC & RESEARCH FOUNDATION,
LA JOLLA , CALIFORNIA

NATIONAL OPINION RESEARCH CENTER,
CHICAGO, ILLINOIS

EPIDEMIOLOGIC RESEARCH DIVISION
ARMSTRONG LABORATORY
HUMAN SYSTEMS CENTER (AFMC)
BROOKS AIR FORCE BASE, TEXAS 78235

2 May 1995

Volume V

1992 Followup Examination Results

May 1992 to May 1995

Contract Number F41624-91-C-1006
SAIC Project Number 01-0813-02-3005

(Distribution Unlimited)

AIR FORCE HEALTH STUDY

An Epidemiologic Investigation of Health Effects in Air Force Personnel Following Exposure to Herbicides

May 1995

Volume V

1995 Followup Examination Results

Epidemiologic Research Division
Armstrong Laboratory
Human Systems Center (AFMC)
Brooks Air Force Base, Texas 78235

TABLE OF CONTENTS

VOLUME V

Page

CHAPTER 17 RENAL ASSESSMENT 17-1

INTRODUCTION 17-1
Background 17-1
Summary of Previous Analyses of the Air Force Health Study 17-2
1982 Baseline Study Summary Results 17-2
1985 Followup Study Summary Results 17-2
1987 Followup Study summary Results 17-3
Serum Dioxin Analysis of 1987 Followup Study Summary Results 17-3
Parameters for the Renal Assessment 17-3
Dependent Variables 17-3
Medical Records Data 17-4
Physical Examination Data 17-4
Laboratory Examination Data 17-4
Covariates 17-4
Statistical Methods 17-5
Longitudinal Analysis 17-5
RESULTS 17-8
Dependent Variable-Covariate Associations 17-8
Exposure Analysis 17-9
Verified Medical Records Variable 17-10
Kidney Disease 17-10
Physical Examination Variable 17-15
Kidney Stones 17-15
Laboratory Examination Variables 17-20
Urinary Protein 17-20
Urinary Red Blood Cell Count 17-20
Urinary White Blood Cell Count 17-29
Serum Creatinine 17-29
Urine Specific Gravity 17-38
Longitudinal Analysis 17-43
Laboratory Examination Variables 17-44
Urinary Protein 17-44
Urinary Red Blood Cell Count 17-44
Urinary White Blood Cell Count 17-44
Urine Specific Gravity 17-54
DISCUSSION 17-54
SUMMARY 17-59
Model 1: Group Analysis 17-59
Model 2: Initial Dioxin Analysis 17-59
Model 3: Categorized Dioxin Analysis 17-68
Models 4, 5, and 6: Current Dioxin Analysis 17-68

TABLE OF CONTENTS (Continued)

Page

CONCLUSION 17-68
REFERENCES 27-69

LIST OF TABLES

		Page
Table 17-1.	Statistical Analyses for the Renal Assessment	17-6
Table 17-2.	Number of Participants with Missing Data for, or Excluded from, the Renal Assessment	17-7
Table 17-3.	Analysis of Kidney Disease	17-11
Table 17-4.	Analysis of Kidney Stones	17-16
Table 17-5.	Analysis of Urinary Protein	17-21
Table 17-6.	Analysis of Urinary Red Blood Cell Count	17-25
Table 17-7.	Analysis of Urinary White Blood Cell Count	17-30
Table 17-8.	Analysis of Serum Creatinine (mg/dl)	17-34
Table 17-9.	Analysis of Urine Specific Gravity	17-39
Table 17-10 .	Longitudinal Analysis of Urinary Protein	17-45
Table 17-11.	Longitudinal Analysis of Urinary Red Blood Cell Count	17-48
Table 17-12.	Longitudinal Analysis of Urinary White Blood Cell Count	17-51
Table 17-13.	Longitudinal Analysis of Urine Specific Gravity	17-55
Table 17-14.	Summary of Group Analyses (Model 1) for Renal Variables (Ranch Hands vs Comparisons)	17-60
Table 17-15.	Summary of Initial Dioxin Analyses (Model 2) for Renal Variables (Ranch Hands Only)	17-62
Table 17-16.	Summary of Categorized Dioxin analyses (Model 3) for Renal Variables (Ranch Hands vs Comparisons)	17-63
Table 17-17.	Summary of Current Dioxin Analyses (Models 4, 5, and 6) for Renal Variables ((Ranch Hands Only)	17-65
Table 17-18.	Summary of Dioxin-by-Covariate Interactions from Analyses of Renal Variables	17-67

TABLE OF CONTENTS

Page

CHAPTER 18 ENDOCRINE ASSESSMENT 18-1

INTRODUCTION 18-1
Background 18-1
Summary of Previous Analyses of the Air Force Health Study 18-2
1982 Baseline Study summary Results 18-2
1985 Followup Study Summary Results 18-3
1987 Followup Study summary Results 18-3
Serum Dioxin Analysis of 1987 Followup Study Summary Results . . . 18-4
Parameters for the Endocrine Assessment 18-4
Dependent Variables 18-4
Medical Records Data 18-4
Physical Examination Data 18-5
Laboratory Examination Data 18-6
Covariates 18-7
Statistical Methods 18-8
Longitudinal Analyses 18-22
RESULTS 18-22
Dependent Variable-Covariate Associations for the Endocrine Assessment . . 18-22
Exposure Analysis 18-32
Medical Records Variable 18-33
Past Thyroid Disease 18-33
Medical Records and Laboratory Variables 18-38
Composite Diabetes Indicator 18-38
Diabetic Severity 18-38
Time to Diabetes Onset 18-51
Physical Examination Variables 18-51
Thyroid Gland 18-51
Testicular Volume: Minimum 18-60
Testicular Volume: Total 18-60
Retinopathy Results (Diabetics) 18-69
Neuropathy Results (Diabetics) 18-74
Radial Pulses (Doppler) (Diabetics) 18-74
Femoral Pulses (Doppler) (Diabetics) 18-79
Popliteal Pulses (Doppler) (Diabetics) 18-79
Dorsalis Pedis Pulses (Doppler) (Diabetics) 18-79
Posterior Tibial Pulses (Doppler) (Diabetics) 18-96
Leg Pulses (Doppler) (Diabetics) 18-101
Peripheral Pulses (Doppler) (Diabetics) 18-101
Thyroid stimulating Hormone (Continuous) 18-110
Thyroid Stimulating Hormone (Discrete) 18-110
Thyroxine (Continuous) 18-119

TABLE OF CONTENTS (Continued)

	Page
Thyroxine (Discrete)	18-119
Anti-Thyroid Antibodies	18-128
Fasting Glucose (All Participants-Continuous)	18-133
Fasting Glucose (All Participants-Discrete)	18-138
Fasting Glucose (Diabetics-Continuous)	18-138
Fasting Glucose (Diabetics-Discrete)	18-147
Fasting Glucose (Nondiabetics-Continuous)	18-152
Fasting Glucose (Nondiabetics-Discrete)	18-157
2-Hour Postprandial Glucose (Continuous)	18-157
2-Hour Postprandial Glucose (Discrete)	18-166
Fasting Urinary Glucose (All Participants)	18-172
Fasting Urinary Glucose (Diabetics)	18-172
Fasting Urinary Glucose (Nondiabetics)	18-181
2-Hour Postprandial Urinary Glucose	18-181
Serum Insulin (All Participants-Continuous)	18-188
Serum Insulin (All Participants-Discrete)	18-193
Serum Insulin (Diabetics-Continuous)	18-200
Serum Insulin (Diabetics-Discrete)	18-200
Serum Insulin (Nondiabetics-Continuous)	18-209
Serum Insulin (Nondiabetics-Discrete)	18-214
Serum Glucagon (All Participants-Continuous)	18-220
Serum Glucagon (All Participants-Discrete)	18-225
Serum Glucagon (Diabetics-Continuous)	18-230
Serum Glucagon (Diabetics-Discrete)	18-230
Serum Glucagon (Nondiabetics-Continuous)	18-239
Serum Glucagon (Nondiabetics-Discrete)	18-239
α-1-C Hemoglobin (All Participants-Continuous)	18-239
α-1-C Hemoglobin (All Participants-Discrete)	18-251
α-1-C Hemoglobin (Diabetics-Continuous)	18-251
α-1-C Hemoglobin (Diabetics-Discrete)	18-260
α-1-C Hemoglobin (Nondiabetics-Continuous)	18-265
α-1-C Hemoglobin (Nondiabetics-Discrete)	18-270
Urinary Protein (Diabetics Only)	18-270
Serum Proinsulin (Continuous)	18-279
Serum Proinsulin (Discrete)	18-279
Serum C Peptide (Continuous)	18-279
Serum C Peptide (Discrete)	18-292
Total Testosterone (Continuous)	18-297
Total Testosterone (Discrete)	18-302
Free Testosterone (Continuous)	18-307
Free Testosterone (Discrete)	18-312
Sex Hormone Binding Globulin	18-317
Total Testosterone to Sex Hormone Binding Globulin Ratio	18-322

TABLE OF CONTENTS (Continued)

Page

Estradiol (Continuous) 18-322
Estradiol (Discrete) 18-322
Luteinizing Hormone (Continuous) 18-335
Luteinizing Hormone (Discrete) 18-340
Follicle Stimulating Hormone (Continuous) 18-340
Follicle Stimulating Hormone (Discrete) 18-349
Longitudinal Analysis 18-349
Medical Records and Laboratory Variable 18-354
Composite Diabetes Indicator 18-354
Laboratory Variables 18-354
Thyroid Stimulating Hormone (TSH) (Continuous) 18-354
Thyroid Stimulating Hormone (Discrete) 18-354
Fasting Glucose (All Participants-Continuous) 18-354
Fasting Glucose (All Participants-Discrete) 18-367
2-Hour Postprandial Glucose (Nondiabetics-Continuous) 18-367
2-Hour Postprandial Glucose (Nondiabetics-Discrete) 18-367
Total Testosterone (Continuous) 18-367
Total Testosterone (Discrete) 18-380
DISCUSSION 18-380
SUMMARY 18-385
Model 1: Group Analysis 18-385
Model 2: Initial Dioxin Analysis 18-411
Model 3: Categorized Dioxin Analysis 18-412
Model 4, 5, and 6: Current Dioxin Analysis 18-413
CONCLUSION 18-414
REFERENCES 18-416

LIST OF TABLES

		Page
Table 18-1.	Statistical Analyses for the Endocrine Assessment	18-9
Table 18-2.	Number of Participants with Missing Data for, or Excluded from, the Endocrine Assessment	18-18
Table 18-3.	Analysis of Past Thyroid Disease	18-34
Table 18-4.	Analysis of Composite Diabetes Indicator	18-39
Table 18-5.	Analysis of Diabetic Severity	18-43
Table 18-6.	Analysis of Time to Diabetes Onset (years)	18-52
Table 18-7.	Analysis of Thyroid Gland	18-56
Table 18-8.	Analysis of Testicular Volume: Minimum (cm^3)	18-61
Table 18-9.	Analysis of Testicular Volume: Total (cm^3)	18-65
Table 18-10.	Analysis of Retinopathy Results (Diabetics)	18-70
Table 18-11.	Analysis of Neuropathy Results (Diabetics)	18-75
Table 18-12.	Analysis of Radial Pulses (Doppler) (Diabetics)18-80	18-80
Table 18-13.	Analysis of Femoral Pulses (Doppler) (Diabetics)	18-84
Table 18-14.	Analysis of Popliteal Pulses (Doppler) (Diabetics)	18-88
Table 18-15.	Analysis of Dorsalis Pedis Pulses (Doppler) (Diabetics)	18-92
Table 18-16.	Analysis of Posterior Tibial Pulses (Doppler) (Diabetics)	18-97
Table 18-17.	Analysis of Leg Pulses (Doppler) (Diabetics)	18-102
Table 18-18.	Analysis of Peripheral Pulses (Doppler (Diabetics)	18-106
Table 18-19.	Analysis of Thyroid-Stimulating Hormone (TSH) (μUI/ml) (Continuous)	18-111
Table 18-20.	Analysis of Thyroid-Stimulating Hormone (TSH) (μIU/ml) (Discrete)	18-115
Table 18-21.	Analysis of Thyroxine (T_4) (μg/dl) (Continuous)	18-120
Table 18-22.	Analysis of Thyroxine (T_4) (Discrete)	18-124
Table 18-23.	Analysis of Anti-Thyroid Antibodies	18-129
Table 18-24.	Analysis of Fasting Glucose (mg/dl) (All Participants) (Continuous)	18-134
Table 18-25.	Analysis of Fasting Glucose (All Participants) (Discrete)	18-139
Table 18-26.	Analysis of Fasting Glucose (mg/dl) (Diabetics) (Continuous)	18-143
Table 18-27.	Analysis of Fasting Glucose (Diabetics) (Discrete)	18-148
Table 18-28.	Analysis of Fasting Glucose (mg/dl) (Nondiabetics) (Continuous)	18-153
Table 18-29.	Analysis of Fasting Glucose (Nondiabetics) (Discrete)	18-158
Table 18-30.	Analysis of 2-Hour Postprandial glucose (mg/dl) (Nondiabetics) (Continuous)	18-162
Table 18-31.	Analysis of 2-our Postprandial glucose (Nondiabetics) (Discrete)	18-167
Table 18-32.	Analysis of Fasting Urinary Glucose (All Participants)	18-173
Table 18-33.	Analysis of Fasting Urinary glucose (Diabetics)	18-177
Table 18-34.	Analysis of Fasting Urinary glucose (Nondiabetics)	18-182
Table 18-35.	Analysis of 2-Hour Postprandial Urinary Glucose (Nondiabetics)	18-184
Table 18-36.	Analysis of Serum Insulin (mIU/ml) (All Participants) (Continuous)	18-189
Table 18-37.	Analysis of Serum Insulin (All Participants) (Discrete)	18-194
Table 18-38.	Analysis of Serum Insulin (mIU/ml) (Diabetics) (Continuous)	18-201
Table 18-39.	Analysis of Serum Insulin (Diabetics) (Discrete)	18-205
Table 18-40.	Analysis of Serum Insulin (mIU/ml) (Nondiabetics) (Continuous)	18-210

LIST OF TABLES (Continued)

		Page
Table 18-41.	Analysis of Serum Insulin (Nondiabetics) (Discrete)	18-125
Table 18-42.	Analysis of Serum Glucagon (pg/ml) (All Participants) (Continuous)	18-221
Table 18-43.	Analysis of Serum Glucagon (All Participants) (Discrete)	18-226
Table 18-44.	Analysis of Serum Glucagon (pg/ml) (Diabetics) (Continuous)	18-231
Table 18-45.	Analysis of Serum Glucagon (Diabetics) (Discrete)	18-235
Table 18-46.	Analysis of Serum Glucagon (pb/ml) (Nondiabetics) (Continuous)	18-240
Table 18-47.	Analysis of Serum Glucagon (Nondiabetics) (Discrete)	18-244
Table 18-48.	Analysis of α-1-C Hemoglobin (All Participants) (Continuous)	18-246
Table 18-49.	Analysis of α-1-C Hemoglobin (All Participants) (Discrete)	18-252
Table 18-50.	Analysis of α-1-C (percent) (Diabetics) (Continuous)	18-256
Table 18-51.	Analysis of α-1-C Hemoglobin (Diabetics) (Discrete)	18-261
Table 18-52.	Analysis of α-1-C Hemoglobin (percent) (Nondiabetics) (Continuous)	18-266
Table 18-53.	Analysis of α-1-C Hemoglobin (Diabetics) (Discrete)	18-271
Table 18-54.	Analysis of Urinary Protein (Diabetics)	18-275
Table 18-55.	Analysis of Serum Proinsulin (ng/ml) (Diabetics) (Continuous)	18-280
Table 18-56.	Analysis of Serum proinsulin (Diabetics) (Discrete)	18-284
Table 18-57.	Analysis of Serum c Peptide (nb/ml) (Diabetics) (Continuous)	18-288
Table 18-58.	Analysis of Serum C Peptide (Diabetics) (Discrete)	18-293
Table 18-59.	Analysis of Total Testosterone (ng/dl) (Continuous)	18-298
Table 18-60	Analysis of Total Testosterone (Discrete)	18-303
Table 18-61.	Analysis of Free Testosterone (pg/ml) (Continuous)	18-308
Table 18-62.	Analysis of Free Testosterone (Discrete)	18-313
Table 18-63.	Analysis of Sex Hormone Binding Globulin	18-318
Table 18-64.	Analysis of total Testosterone to sex Hormone Binding Globulin Ratio	18-323
Table 18-65.	Analysis of Estradiol (pg/ml) (Continuous)	18-327
Table 18-66.	Analysis of Estradiol (Discrete)	18-331
Table 18-67.	Analysis of Luteinizing Hormone (LH) mIU/ml) (Continuous)	18-336
Table 18-68.	Analysis of Luteinizing Hormone (LH) (Discrete)	18-341
Table 18-69.	Analysis of Follicle Stimulating Hormone (FSH) (mIU/ml) (Continuous)	18-345
Table 18-70.	Analysis of Follicle Stimulating Hormone (FSH) (Discrete)	18-350
Table 18-71.	Longitudinal Analysis of Composite Diabetes Indicator	18-355
Table 18-72.	Longitudinal Analysis of Thyroid Stimulating Hormone (μIU/ml) (TSH) (Continuous)	18-358
Table 18-73.	Longitudinal Analysis of Thyroid Stimulating Hormone (TSH) (Discrete)	18-361
Table 18-74.	Longitudinal Analysis of Fasting Glucose (mg/dl) (All Participants) (Continuous)	18-364
Table 18-75.	Longitudinal Analysis of Fasting Glucose (All Participants) (Discrete)	18-368
Table 18-76.	Longitudinal Analysis of 2-Hour Postprandial Glucose (mg/dl) (Nondiabetics) (Continuous)	18-371

LIST OF TABLES (Continued)

Page

Table 18-77. Longitudinal Analysis of 2-Hour Postprandial Glucose (Nondiabetics) (Discrete) 18-374
Table 18-78. Longitudinal Analysis of Total Testosterone (ng/dl) (Continuous) . . . 18-377
Table 18-79. Longitudinal analysis of Total Testosterone (Discrete) 18-381
Table 18-80. Summary of Group Analyses (Model 1) for Endocrine Variables (Ranch Hands vs Comparisons) 18-386
Table 18-81. Summary of Initial Dioxin Analyses (Model 2) for Endocrine Variables (Ranch Hands Only) 18-392
Table 18-82. Summary of Categorized Dioxin Analyses (Model 3) for Endocrine Variables (Ranch Hands vs Comparisons) 18-395
Table 18-83. Summary of Current Dioxin Analyses (Models 4, 5, and 6) for Endocrine Variables (Ranch Hands Only) 18-402
Table 18-84. Summary of Group-by-Covariate and Dioxin-by-Covariate Interactions from Adjusted Analyses of Endocrine Variables 18-408

TABLE OF CONTENTS - REPORT

VOLUME I	EXECUTIVE SUMMARY
	ACKNOWLEDGEMENTS
	CHAPTER 1 - Introduction
	CHAPTER 2 - The Dioxin Assay
	CHAPTER 3 - Questionnaire Methodology
	CHAPTER 4 - Physical examination Methodology
	CHAPTER 5 - Study Selection and Participation
	CHAPTER 6 - Quality Control
	CHAPTER 7 - Statistical Methods
	CHAPTER 8 - Covariate Associations with Estimates of Dioxin Exposure
	CHAPTER 9 - General Health Assessment
VOLUME II	CHAPTER 10 - Neoplasia Assessment
	CHAPTER 11 - Neurological Assessment
VOLUME III	CHAPTER 12 - Psychological Assessment
	CHAPTER 13 - Gastrointestinal Assessment
VOLUME IV	CHAPTER 14 - Dermatologic Assessment
	CHAPTER 15 - Cardiovascular Assessment
	CHAPTER 16 - Hematologic Assessment
VOLUME V	CHAPTER 17 - Renal Assessment
	CHAPTER 18 - Endocrine Assessment
VOLUME VI	CHAPTER 19 - Immunologic Assessment
	CHAPTER 20 - Pulmonary Assessment
	CHAPTER 21 - Conclusions
	CHAPTER 22 - Future Directions
VOLUME VI	APPENDIX A - 1 through F-2
VOLUME VII	APPENDIX G - 1 through I-4
VOLUME IX	APPENDIX J - 1 through N-4
VOLUME X	APPENDIX 0 - 1 through R